美国儿童和青少年多系统炎症综合征研究
该研究对美国26个州186例MIS-C患儿进行靶向监测,发现多数患儿既往健康,SARS-CoV-2检测阳性或暴露史明确,常见多系统器官受累,重症监护需求高,但冠状动脉动脉瘤和死亡比例较低。
要点
- MIS-C可导致既往健康儿童和青少年严重甚至危及生命的疾病。
- 常见受累系统包括胃肠道、心血管、血液、皮肤黏膜和呼吸系统。
- 多数患儿需要重症监护,免疫调节治疗使用普遍。
核心结论
- 与SARS-CoV-2相关的儿童多系统炎症综合征可导致既往健康的儿童和青少年出现严重且危及生命的疾病。
研究设计与样本
- 2020年3月15日至5月20日在美国儿科健康中心开展靶向监测,报告26个州186例MIS-C患者。
主要发现
- 中位年龄8.3岁,115例(62%)为男性,135例(73%)既往健康。
- 131例(70%)SARS-CoV-2 RT-PCR或抗体检测阳性,164例(88%)在2020年4月16日之后住院。
- 器官系统受累:胃肠道171例(92%),心血管149例(80%),血液142例(76%),皮肤黏膜137例(74%),呼吸131例(70%)。
- 中位住院时间7天(四分位距4至10),148例(80%)接受重症监护,37例(20%)接受机械通气,90例(48%)接受血管活性药物支持,4例(2%)死亡。
- 冠状动脉动脉瘤(z评分≥2.5)15例(8%),川崎病样特征74例(40%),171例(92%)至少四种炎症生物标志物升高。
关键数值与推荐
- 病例定义包括六项标准:严重疾病导致住院、年龄小于21岁、发热持续至少24小时、实验室炎症证据、多系统器官受累、SARS-CoV-2感染证据(RT-PCR、抗体检测或过去一个月内接触新冠患者)。
- 免疫调节治疗:静脉注射免疫球蛋白144例(77%),糖皮质激素91例(49%),白介素-6或1RA抑制剂38例(20%)。
临床怎么用
- 对符合病例定义的儿童和青少年应考虑MIS-C,及时评估多系统受累并给予重症监护支持。
- 免疫调节治疗(如静脉免疫球蛋白、糖皮质激素)在MIS-C中应用普遍,需根据病情个体化使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome. METHODS: We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms. RESULTS: We report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were documented in 15 patients (8%), and Kawasaki's disease-like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%). CONCLUSIONS: Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.).
引用
- Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020. PMID: 32598831. doi:10.1056/NEJMoa2021680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。